Ipsen Expands Oncology Portfolio with $247 Million Epizyme Acquisition

Ipsen will acquire Epizyme, who recently had their lead medicine Tazverik (tazemetostat) approved by FDA for treatment of relapsed or refractory follicular lymphoma.